EquityBulls

Latest News

Anand Rayons Ltd receives approval for STAPII trademark
IRFC extends funding support to PVUNL for INR 3,388.51 crore
Zaggle Prepaid Ocean Services Ltd enters into agreement with IDFC First Bank Ltd
PNG Jewellers expands National Footprint, Celebrates Lucknow's Cultural Legacy with Maiden Store Launch
Interarch strengthens presence in Multi-Storey Steel Buildings with new plant in Attivaram, Andhra Pradesh

Keywords Selected: ZydusLifesciences

Stock Report

Zydus and Pinkathon join hands to drive awareness on breast cancer across India
Zydus receives EIR for the oncology injectable manufacturing facility in SEZ1, Ahmedabad
ZyVet® launches affordable Furosemide tablets to support long-term heart care trusted diuretic for dogs and cats now available in a generic form
ZyVet® Launches First Generic Treatment for Canine Urinary Incontinence
Closure of USFDA inspection at Zydus' injectable manufacturing plant at Jarod
Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules for the U.S. market
Zydus launches VaxiFlu™ India's first trivalent influenza vaccine for flu protection
Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
Zydus receives final approval from USFDA for Prucalopride Tablets, 1 mg and 2 mg
Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 & 1 mg
Zydus announces completion of the acquisition of an 85.6% stake in Amplitude Surgical
Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg
Closure of Remote Regulatory Assessment by the USFDA at Matoda, Gujarat facility
Zydus receives final approval from USFDA for Celecoxib Capsules, 50 mg, 100 mg, 200 mg and 400 mg
Closure of USFDA inspection at Zydus' oncology injectable plant at Ahmedabad
Zydus receives EIR for the API manufacturing facility at Ankleshwar
Zydus receives EIR for the API manufacturing facility at Dabhasa
Zydus enters global biologics CDMO business, plans to acquire Agenus’ U.S. manufacturing facilities to accelerate development of innovative therapies
Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
Zydus receives final approval from USFDA for Isotretinoin Capsules USP, 10 mg 20 mg, 25 mg, 30 mg, 35 mg and 40 mg
Zydus receives EIR for the Ambernath API manufacturing facility
Zydus Lifesciences completes 25 years of listing on NSE, commemorated with a bell ringing ceremony at NSE
Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg
Closure of USFDA inspection at Zydus' API Unit at Dabhasa, Gujarat